Literature DB >> 22526457

CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.

Carlos Monteagudo1, David Ramos, Ana Pellín-Carcelén, Rosario Gil, Robert C Callaghan, José M Martín, Vicent Alonso, Amelia Murgui, Lara Navarro, Silvia Calabuig, José Antonio López-Guerrero, Esperanza Jordá, Antonio Pellín.   

Abstract

CXCR4, CCR7 and CCR10 chemokine receptors are known to be involved in melanoma metastasis. Our goal was to compare the relative intratumoral mRNA expression of these receptors with that of their corresponding chemokine ligands, CXCL12, CCL19, CCL21, and CCL27 across the full spectrum of human melanoma progression: thin and thick primary melanomas, as well as "in transit", lymph node, and distant metastases. Expression was quantified by real-time RT-PCR in 103 melanoma samples: 51 primary tumors and 52 metastases. Particular emphasis was focused on chemokine ligand-receptor expression ratios. Immunohistochemistry was performed to identify the cell types expressing these molecules. CXCL12-CXCR4 and CCL27-CCR10 ratios were higher in thin than in thick primary melanomas, and all four chemokine-receptor ratios were higher in primary tumors than in melanoma metastases. CCL27-CCR10 and CXCL12-CXCR4 expression ratios in primary tumors were inversely associated with the development of distant metastases, and improved the predictive value of tumor thickness for distant metastasis, which is important since chemokine ligand-receptor ratios are not affected by the endogenous gene employed for normalizing mRNA expression. Both receptor and ligand immunolabeling were detected in neoplastic cells suggesting autocrine mechanisms. Our results support the concept that low CCL27/CCR10 and CXCL12/CXCR4 intratumoral mRNA ratios are associated with melanoma progression, and in combination with Breslow thickness, are the best predictive factors for the development of distant metastases in primary cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526457     DOI: 10.1007/s10585-012-9476-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  61 in total

1.  Lessons learned from lymphocytes: CC chemokine receptor-7 involved in lymphogenic metastasis of melanoma.

Authors:  R Förster; L Ohl; G Henning
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

2.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

3.  Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma.

Authors:  H E Wiley; E B Gonzalez; W Maki; M T Wu; S T Hwang
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

Review 4.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs.

Authors:  Rubén A Bartolomé; Sergio Ferreiro; María E Miquilena-Colina; Lorena Martínez-Prats; María L Soto-Montenegro; David García-Bernal; Juan J Vaquero; Reuven Agami; Rafael Delgado; Manuel Desco; Paloma Sánchez-Mateos; Joaquin Teixidó
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 6.  Recent progress in understanding the pathology of malignant melanoma.

Authors:  Silke Kuphal; Anja Bosserhoff
Journal:  J Pathol       Date:  2009-12       Impact factor: 7.996

7.  Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells.

Authors:  Evemie Schutyser; Yingjun Su; Yingchun Yu; Mieke Gouwy; Snjezana Zaja-Milatovic; Jo Van Damme; Ann Richmond
Journal:  Eur Cytokine Netw       Date:  2007-06-26       Impact factor: 2.737

Review 8.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

9.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

10.  Immune evasion by murine melanoma mediated through CC chemokine receptor-10.

Authors:  Takashi Murakami; Adela R Cardones; Steven E Finkelstein; Nicholas P Restifo; Brenda A Klaunberg; Frank O Nestle; S Sianna Castillo; Phillip A Dennis; Sam T Hwang
Journal:  J Exp Med       Date:  2003-10-27       Impact factor: 14.307

View more
  16 in total

1.  Expression of the Chemokine Receptors CXCR3, CXCR4, CXCR7 and Their Ligands in Rhabdomyosarcoma.

Authors:  Teresa San-Miguel; Sandra Pinto; Lara Navarro; Robert C Callaghan; Carlos Monteagudo; Concha López-Ginés; Miguel Cerdá-Nicolás; Rosario Gil-Benso
Journal:  Pathol Oncol Res       Date:  2015-06-03       Impact factor: 3.201

Review 2.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 3.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

4.  Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Authors:  Nicolas Jacquelot; David P Enot; Caroline Flament; Nadège Vimond; Carolin Blattner; Jonathan M Pitt; Takahiro Yamazaki; María Paula Roberti; Romain Daillère; Marie Vétizou; Vichnou Poirier-Colame; Michaëla Semeraro; Anne Caignard; Craig L Slingluff; Federica Sallusto; Sylvie Rusakiewicz; Benjamin Weide; Aurélien Marabelle; Holbrook Kohrt; Stéphane Dalle; Andréa Cavalcanti; Guido Kroemer; Anna Maria Di Giacomo; Michele Maio; Phillip Wong; Jianda Yuan; Jedd Wolchok; Viktor Umansky; Alexander Eggermont; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2016-02-08       Impact factor: 14.808

Review 5.  Targeting regulatory T cells for immunotherapy in melanoma.

Authors:  Lili Huang; Yeye Guo; Shujing Liu; Huaishan Wang; Jinjin Zhu; Lingling Ou; Xiaowei Xu
Journal:  Mol Biomed       Date:  2021-04-19

6.  CCR10/CCL27 crosstalk regulates cell metastasis via PI3K-Akt signaling axis in non-small-cell lung cancer.

Authors:  Yonggang Liu; Ailian Xiao; Biyuan Zhang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

7.  Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival.

Authors:  Lingchao Chen; Xing Liu; Hai-Yan Zhang; Wenzong Du; Zhiyong Qin; Yu Yao; Ying Mao; Liangfu Zhou
Journal:  Oncotarget       Date:  2014-08-30

Review 8.  CCL27 Signaling in the Tumor Microenvironment.

Authors:  Miguel Martínez-Rodríguez; Carlos Monteagudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation.

Authors:  Sandra Pinto; Alicia Martínez-Romero; José-Enrique O'Connor; Rosario Gil-Benso; Teresa San-Miguel; Liria Terrádez; Carlos Monteagudo; Robert C Callaghan
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

10.  The Research on the Treatment of Metastatic Skin Cutaneous Melanoma by Huanglian Jiedu Decoction Based on the Analysis of Immune Infiltration Analysis.

Authors:  Ding Li; Shi-Fang Li; Xiao-Yuan Li; Xiao-Wei Sun; Tian-Yue Sun; Guo-Jie Hu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.